A B S T R A C T The two pyrazolon derivatives, phenylbutazone and sulfinpyrazone, selectively inhibit chemotactic peptide-induced effects on neutrophils. As they antagonize the induction of acute neutropenia in vivo and of cellular hyperadhesiveness, lysosomal enzyme release, hexose monophosphate shunt activity, and superoxide production in vitro, these effects occur with a specificity not shared with other prostaglandin biosynthesis inhibitors. Inhibition by these drugs resembles the competitive type ofantagonism and occurs at concentrations attainable in vivo under clinical conditions. The locomotory machinery, the directionfinding mechanisms, and the basic metabolic machinery ofthe cell are unaffected. These drugs interfere with specific binding of the formylpeptide to its receptor on neutrophils.
INTRODUCTION
Recent research on the polymorphonuclear leukocytes (PMN)' has concentrated predominantly on their role in the host defense against invading microorganisms, resulting in the elaboration ofthe mechanisms involved in the phagocytic and microbicidal potency of these cells. The functional basis of many rare defects of these cells has been worked out elegantly along these lines (1, 2) . However, such studies have also made 884 it evident that normal PMN possess an "overkill" capacity that may be detrimental to the host if an inflammatory response is misdirected or excessive, leading to self damage (3) . We have recently shown (4) that the exposure of PMN to synthetic chemotactic peptides at concentrations higher than those required for chemotaxis induce a highly reactive, probably cytotoxic (5) cellular condition. This is characterized by immobilizing hyperadhesiveness and spreading, accompanied by degranulation with enzyme release and stimulation of the hexose monophosphate pathway (HMP) activity, the latter phenomenon also reflecting superoxide production (6) . Having in mind that mitigation of PMN overstimulation might be a promising way to modulate inflammatory processes, we looked for pharmacologic principles that are antagonistic to chemotactic peptide-induced PMN alterations. METHODS PMN were prepared from normal human volunteers by means of Ficoll-Hypaque density separation (96-99% PMN, 1-4% eosinophils). After hypotonic lysis oferythrocytes, PMN were washed twice in Gey's solution (Gibco Diagnostics, Glasgow, Scotland) and, if not stated otherwise, suspended in 95-100% pure heat-inactivated autologous plasma (4) . N-formyl-MetLeu-Phe (fMLP) was obtained from Bachem AG, Bubendorf, Switzerland. Phenylbutazone (PB) and sulfinpyrazone (SP) were gifts from Ciba-Geigy Ltd., Basel, Switzerland, and indomethacin was from Merck Sharp and Dohme, Rahway, N. J.; aspirin, inulin, and pepstatin A was purchased from Sigma Chemical Co. (St. Louis, Mo.). fMLP, SP, PB, and aspirin were dissolved in a small volume of 0.15 N NaOH and diluted in phosphate-buffered saline, pH 7.4 (PBS); fMLP, SP, and aspirin solutions were adjusted to pH 7.4 with 0.15 N HCI while PB was added to plasma in alkali solution.
Three parts of indomethacin with one part Na2CO3 (wtlwt), was dissolved in PBS followed by adjustment of the pH with 0.15 N HCI. Drugs did not change plasma pH and plasma dilution by drug addition was --1% (vol/vol). Drug solutions were prepared fresh and added to experimental cell suspen-sions without any delay. PMN adherence, glucose oxidation by the HMP, and chemotaxis in Boyden chambers were quantitated as previously described (4) . For chemotaxis, results are given in cells per high power field and represent means±SD of triplicates; in each case, experiments were repeated twice showing similar results. For glucose oxidation by the HMP, the incubation procedure was slightly modified in so far as the generation of 14CO2 from [1-'4C]glucose was determined with PMN incubated in petri dishes (identical to adherence assay) instead of keeping them in shaken tubes. To ensure an air-tight system, covers of the dishes containing the C02-trapping device were sealed with petroleum jelly. The influence of SP/PB on latex-or Candida-stimulated HMP activity (as a measure of the phagocytosis-induced "respiratory burst" was assessed in shaking tubes. Latex was used as previously (4) and Candida albicans were grown under established conditions (7), heat-killed, washed once in PBS, and opsonized with fresh serum by rotating in a capped sterile tube for 30 min at 37°C; they were washed once more in PBS and added to the PMN in heat-inactivated plasma (with and without the drug) at a ratio of 10:1. As an indicator for lysosomal enzyme release during adherence, net release ofa sensitive marker for secondary granule constituents, the PMNassociated vitamin B12 binding protein (8) was measured in the supemates of the petri dishes by the relative absorption of 57Co-B12 (9) . Appropriate controls excluded direct effects of the drugs tested on the B12 binding assay. Similar results were obtained by measuring lysozyme release (4) .
Superoxide generation was assayed as described (10) using a dual-wavelength (550 vs. 540 nm) spectrophotometer (Shimadzu Seisakusho, Ltd., model UV 300, Kyoto, Japan). fMLP-induced 0°production was measured with PMN suspended in Krebs-Ringer-phosphate buffer (pH 7.4) containing 0.5 mg/ml glucose and 0.5% highly purified human albumin (Behring Corp., Marburg, West Germany). PMN (5 x 10f) were kept in a stirred thermostated cell compartment; the continuously monitored change in absorbance, which followed the addition of fMLP, was always completed within 2-3 min, and was 28±5 nM (mean±SD, n = 12) ferricytochrome c reduced/5 x 108 PMN for maximal stimulation.
The radioligand binding assay for f-Met-Leu-[3H]Phe (New England Nuclear, Boston, Mass.; 56.9 Ci/mmol sp act) was performed as described (11) , except that the PMN suspension medium was autologous heat-inactivated plasma.
For studies in animals, New Zealand white rabbits (2.5-3.5 kg) were used, with sterile cannulas inserted in an ear vein for infusion of agents and into an ear artery for blood sampling.
RESULTS
In the rabbit model, intravenous administration of the potent chemoattractant fMLP (12) induces a profound transient granulocytopenia by excessive PMN margination (4, 13) . Premedication of animals with as little as 10 mg/kg SP completely abolished an agranulocytotic response of5 min duration after a bolus of2.5 nmol of fMLP (Fig. 1A) . Although similar results were obtained with the structurally related PB, the need for intramuscular administration meant that the drug was not suitable for exact dose-response studies. Nevertheless, a single injection of 50 mg/kg i.m. PB 5-6 h before fMLP administration abolished an identical agranulocytotic response completely. In contrast, two classic prostaglandin biosynthesis inhibitors, indomethacin (in doses as high as 25 mg/kg; Fig. IA ) and aspirin (up to 150 mg/kg; not shown), had no effect on this biologic activity offMLP. To obtain information on the nature of the inhibition, untreated, as well as animals pretreated with a constant amount of SP, were given varying doses of fMLP. As illustrated in Fig. 1B , a parallel shift to the right of the dose-response curve was observed, as is expected for a competitive antagonist. Using a mean measured plasma level of SP of 270+40 (SD) ,ug/ml, which was found in samples obtained 20 min after drug administration (n = 3; method according to ref. 14) , and assuming no essential immediate extravasation or destruction of fMLP, a rough estimation of the dissociation constant for the antagonist (&d) (15) around a value of 21 ,uM can be obtained.
Because the fM LP-induced granulocytopenia in the rabbit might be an in vivo expression of an increase in PMN adhesiveness occurring intravascularly (4) , the influence of PB and SP on fMLP-induced granulocyte adherence was studied in vitro. In all our in vitro systems, we kept the cells in 95-100% pure autologous plasma to represent the physiologic situation as closely as possible. As depicted in Fig. 2A , both drugs shifted the dose-response curve for adhesion induction with a similar potency to the right. From these curves, estimates for the Kd values are 80 ,uM (25 ,ug/ml) for PB and 30 A.M (14 ,ug/ml) for SP, respectively. In addition, close parallelism was observed for the inhibition of the adherence-induced lysosomal enzyme release that predominantly affects constituents of the secondary granules (Fig. 2B ). It is unlikely that PB and SP act by interfering with the arachidonic acid metabolism of PMN, as two potent inhibitors of this system were without any effect on a submaximal response to 0.1 AM fMLP in the petri dish assay (no significant influence on adherence nor on the release of B,2-binding protein or lysozyme): this was the case for pretreatment of PMN (a) with aspirin up to 300 A.g/ml (1.7 mM), a dose that blocks prostaglandin biosynthesis in platelets, endothelial cells, and fibroblasts (16) , and (b) with indomethacin up to 250 p.g/ml (0.7 mM), a concentration far higher than that required to prevent thromboxane production (17) or the inhibition of the phospholipase A2 activity (18) in PMN. Because PMN suspended in the presence of hyperadhesion-inducing concentrations offMLP show marked alterations in oxygen metabolism (4, 6) , the influence of the two pyrazolon derivatives on the fMLP-induced HMP activation was also assessed on petri dishes. Fig. 3A shows that PB was again a competitive antagonist for such HMP stimulation (Kd 13,uM). Fig. 3B represents an experiment in which various doses of the antagonist PB were used whereas the concentration ofthe agonist was kept constant. Virtually identical results were obtained with SP, whereas aspirin and indomethacin at the above mentioned concentrations were again ineffective. (20 ,ug/ml) had no effect upon fMLP-stimulated 02 generation.
As compiled in Table I , PB and SP at concentrations used in these studies do not impede the basic locomotory activity (random migration) of PMN when tested in chemotactic chambers (A). However, they do blunt directed migration toward a chemotactic concentration offMLP (B). In contrast, migration toward complementderived chemotactic factors (10% inulin-activated plasma [4] ) (C) was absolutely unimpeded. Furthermore, the drastically reduced PMN locomotion at adhesion-inducing concentrations of fMLP could be overcome, at least partly, in the presence of 250 ug/ml PB or SP; this was the ease for random migration (D) as well as for chemotaxis toward 10% inulin-activated plasma (E).
In the light ofprevious studies that had shown inhibition of HMP activity by PB (19, 20) , it was indicated to repeat such studies under our assay conditions using autologous heat-inactivated plasma instead of proteinfree buffer solutions as the suspension medium. Applying two different stimuli for the activation of the HMP, one representing a complement-independent (latex), the other a complement (C3b)-dependent stimulus (opsonized Gandida), we found absolutely no curtailment of [1-14C] (21) , and, therefore, the measured alteration in cell-associated radioactivity could also be the consequence ofan influence ofthe drugs on this or a later step in the uptake process, the binding and blocking studies for SP were also performed at 0°C, a temperature where internalization does not occur (21, 22) . Under these conditions, with ligand-cell interaction for 60 min at 0°C, 10 times lower binding of f-Met-Leu-[3H]Phe to the cells was observed causing a relative increase in nonspecific binding to 40-45%. Nevertheless, the curve for the SP-inhibited specific binding of the labeled peptide showed close parallelism to the one obtained at 37°C, and resulted in an EC50 of 40 ,ug/ml (98 ,uM).
From our results obtained in the experiments dealing with chemotaxis (Table I) , it can be inferred that SP/PB may represent selective inhibitors for fMLP-induced PMN stimulation, and that these drugs do not impair responses to complement-derived stimuli. The following experiments were conducted to answer this question more clearly. First, in the rabbit model (23) , rapid (1 min) administration of 2.5 ml i.v. of autologous inulin-activated plasma produced a complete agranulocytotic response of 5 min duration, with clearly visible PMN recirculation at 10 min. Pretreatment of animals with 50 mg/kg SP (procedure as given for Fig. 1 A, B) had absolutely no attenuating effect on this granulocytopenia (n = 3). Second, Fig. 5A -C depicts the in vitro results obtained with human PMN exposed to different concentrations of complement(inulin)-activated plasma in the presence and absence of SP (not shown are identical results obtained with PB). In contrast to the stimulation with fMLP (Figs. 2 and 3) , no inhibitory potency can be ascribed to this drug with respect to complement-derived stimuli (presumably C5a). Third, because in our laboratory fMLP (1-10 nM) was a less potent chemotaxin (which means that it induced a smaller number of cells to migrate) than 10% inulinactivated plasma, the influence of PB/SP on PMN migration toward lower concentrations of activated plasma was also assessed. As visible in Table I (F and G) we found also no significant inhibition of such reduced migration at suboptimal concentrations of complement-activated plasma. olon derivatives in their role as inhibitors of fMLP receptor-mediated PMN activation came from studies with pepstatin. Pepstatin, a naturally occurring microbial pentapeptide, is a potent chemotaxin for human PMN and shares a common receptor with fMLP on these cells (24) . It does so despite its diverse primary structure and possession of an antigenicity different from the one elicited by fMLP (25) . As compiled in Table II at the concentrations indicated on the abscissa (log scale). Results are expressed as percent inhibition of "specific" binding (11 tic properties against chemotactic peptide-induced PMN alterations. The findings allow us (a) to define a clinically applicable pharmacologic antagonist of a receptor-specific PMN chemotoxin, and (b) to provide a novel mechanism of action for a nonsteroidal antiinflammatory drug class that obviously interferes at an early step of the peptide-PMN interaction and is not dependent on the inhibition of the classic prostaglandin biosynthesis. SP and PB seem to be selective in competing with the agonists of a relatively well defined PMN receptor that shows specificity for Nblocked hydrophobic peptides (e.g., N-formyl peptides and pepstatin); obviously, these drugs do not interfere with identical biologic responses elicited by complement-derived chemotactic factors that are presumably mediated by the CSa receptor. In spite of receptordirected specificity, the question whether SP and PB compete directly for peptide binding at the same receptor or ifthey modulate cell-peptide interaction by binding to an allosteric site cannot be answered by our study. Although we are well aware of the many discrepancies between presented and earlier results obtained in studies on pharmacological modulation of PMN function by nonsteroidal anti-inflammatory drugs, our findings stress the importance for adequate in vitro models. On the one hand, the strikingly close quantitative correspondence between the in vivo and in vitro inhibitory potency of SP and PB on fMLP- In the absence of pepstatin, no statistical difference exists between E) and 0 ; in the presence of pepstatin, P of (0 vs. e is <0.001 (Student's t test).
induced neutropenia and adhesiveness, respectively, stands in favor of our methods. On the other hand, our results cast doubt on the physiologic relevance of studies showing inhibitory activity of indomethacin on several fMLP-induced PMN alterations in protein-free buffer systems (26) (27) (28) , an activity that was completely lost upon addition of albumin (27, 28) or heat-inactivated serum (28) . Although it is certainly premature to decide firmly on the clinical relevance ofour observations, especially as long as it remains unknown whether complement (C5a) or peptide receptor-mediated PMN hyperstimulation is more important for an uncontrolled and tissue damaging PMN reactivity, our findings provide us with a new and highly desirable (29) pharmacologic approach to anti-inflammatory therapy and may allow us to modulate the "fine tuning" of inflammation (30) . We have indeed strong evidence from limited patient studies that pharmacological mitigation of hyperreactive PMN is achievable in vivo, which indicates that triggering of PMN by naturally arising undefined analogs of chemotactic peptides is also accessible to modulation by these drugs. In this context, preliminary in vitro results suggest that PMN adhesion to and spreading on immunoglobulin-coated surfaces is also decreased by PB/SP.
As recently demonstrated, SP is clinically effective in lowering the frequency of cardiac deaths after myocardial infarction (31) . Because myocardial necrosis can be reduced by limiting the acute inflammatory response in the animal (32, 33) and since the reason for the beneficial action of SP in the postinfarction patient remains elusive and may be unrelated to its inhibitory effect on platelets (34), we might suggest that one possible way by which SP achieved its effect was by diminishing the PMN-dependent cytotoxic reactions.
Based on the fact that SP and PB probably act as competitive antagonists in our system, it is dictated by pharmacokinetic conditions that, in spite of similar in vitro potency of the two pyrazolon derivatives, PB remains the more potent drug in vivo. PB has a plasma half-life of 72 h, and presently used repeated clinical dosing (600 mg/d) leads to plasma levels between 50 and 150 ,ug/ml (35) , whereas SP has a plasma half-life of 2.5 h, and a simple peroral dose of 200 mg leads to a maximal plasma level of -20 ug/ml within 1-2 h (36). It is now a challenge to biochemical research to define the structure-effect principle more precisely and to look for chemical modifications of the indispensable structure in favor of higher effectiveness and lower toxicity.
